All sponsors

Amgen $AMGN

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS67
PHASE 3 / 2-350
RECRUITING30
READOUTS ≤12 MONTHS18
READOUT SLIPPED >6 MO54%

Delay Index: of 52 active trials registered more than a year ago, 28 have moved their primary completion (readout) date by more than 6 months since first registration (median +10.3 months). See all sponsors →

Open Amgen on the live radar map → 📅 $AMGN readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Inebilizumab
NCT04540497
P3Active, not recruitingIgG4 Related Disease1352024-04-09 (+10 mo)
MINT
NCT04524273
P3Active, not recruitingMyasthenia Gravis2382024-05-28 (+11 mo)
DeLLphi-304
NCT05740566
P3Active, not recruitingSmall Cell Lung Cancer (SCLC)5092025-01-29 (-5 mo)
DeLLphi-307
NCT06502977
P2Active, not recruitingExtensive Stage Small Cell Lung Cancer322025-03-28 (-6 mo)
Maridebart Cafraglutide
NCT06660173
P2Active, not recruitingType 2 Diabetes Mellitus (T2DM)4092025-10-06
OASIS(EM)
NCT03836040
P3Active, not recruitingMigraine4572025-11-19 (+36 mo)
Teprotumumab
NCT06248619
P3Active, not recruitingThyroid Eye Disease892025-12-23 (+3 mo)
Blinatumomab
NCT06054113
P2Active, not recruitingB Precursor Acute Lymphoblastic Leukemia; Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia182026-01-06 (+2 mo)
Romiplostim
NCT03937154
P3Active, not recruitingChemotherapy-induced Thrombocytopenia1452026-03-10 (+54 mo)
Dazodalibep
NCT06245408
P3Active, not recruitingSjögren's Syndrome (SS)4342026-10-22 (+8 mo)
anvumetostat
NCT06593522
P2Active, not recruitingMTAP-deleted NSCLC612026-10-31 (-10 mo)
MTAPESTRY 101
NCT05094336
P1/2Active, not recruitingAdvanced MTAP-null Solid Tumors3292026-11-30 (+25 mo)
Eucalyptus
NCT06430866
P3Active, not recruitingEarly-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)1632026-12-14 (+12 mo)
AMG 732
NCT06401044
P1/2Active, not recruitingThyroid Eye Disease942027-01-06 (-5 mo)
MARITIME-1
NCT06858839
P3Active, not recruitingObesity38532027-01-21
MARITIME-2
NCT06858878
P3Active, not recruitingType 2 Diabetes Mellitus (T2DM), Obesity, Overweight11052027-01-21
Inebilizumab
NCT05549258
P2RecruitingNeuromyelitis Optica Spectrum Disorder152027-04-13 (+31 mo)
Ocrelizumab (US)
NCT06700343
P3Active, not recruitingRelapsing-remitting Multiple Sclerosis (RRMS)1522027-04-19 (+3 mo)
MARITIME-3-J
NCT06987695
P3Active, not recruitingObesity Disease2792027-04-27 (-3 mo)
Romosozumab
NCT05972551
P3Active, not recruitingOsteogenesis Imperfecta1112027-05-04 (+2 mo)
MARITIME-PEN
NCT07871409
P3RecruitingObesity; Overweight2302027-06-16
Etelcalcetide
NCT03969329
P3RecruitingSecondary Hyperparathyroidism242027-06-30 (+60 mo)
Sotorasib
NCT05920356
P3RecruitingNon-Small Cell Lung Cancer (NSCLC)7502027-06-30 (+19 mo)
Avacopan
NCT06321601
P3Active, not recruitingVasculitis192027-07-18 (-33 mo)
ABP 938 8 mg
NCT07614776
P3RecruitingNeovascular Age-related Macular Degeneration; nAMD3042027-07-31
MARITIME-OSA-1
NCT07225686
P3Active, not recruitingObesity; Obstructive Sleep Apnea2502027-08-20 (-1 mo)
Maridebart cafraglutide
NCT07441252
P2Active, not recruitingOverweight or Obesity and Elevated Liver Fat1802027-08-25
MARITIME-OSA-2
NCT07226765
P3Active, not recruitingObstructive Sleep Apnea2502027-08-30
DeLLphi-315
NCT07778316
P3RecruitingSmall Cell Lung Cancer4002027-09-24
Blinatumomab
NCT04521231
P1/2Active, not recruitingB Cell Precursor Acute Lymphoblastic Leukemia1812027-11-24 (+57 mo)
Maridebart Cafraglutide
NCT07684144
P3RecruitingObesity; Overweight9502027-12-26
Maridebart cafraglutide
NCT07684235
P3RecruitingObesity; Overweight32002027-12-26
DeLLphi-301
NCT05060016
P2Active, not recruitingRelapsed/Refractory Small Cell Lung Cancer2222027-12-30 (+51 mo)
Maridebart Cafraglutide
NCT07575399
P3RecruitingObesity or Overweight3002028-01-03
ABP 234
NCT06311721
P3Active, not recruitingAdvanced or Metastatic Non-squamous Non-Small Cell Lung Cancer3152028-01-10 (+3 mo)
ABP 206
NCT06054555
P3Active, not recruitingMelanoma6332028-01-25 (+12 mo)
HAZEL 401
NCT07438405
P2RecruitingThyroid Eye Disease302028-01-29
PEAPOD
NCT04804553
P3RecruitingActive Juvenile Psoriatic Arthritis602028-03-21 (+40 mo)
Olpasiran
NCT05581303
P3Active, not recruitingAtherosclerotic Cardiovascular Disease72972028-03-31 (+15 mo)
Vitamin D
NCT07366086
P3RecruitingOsteogenesis Imperfecta712028-04-19
OCEAN(a)-CCTA
NCT07293260
P3RecruitingCardiovascular Disease4062028-06-15
Pegloticase
NCT07388498
P3RecruitingUncontrolled Gout2702028-06-18
MARITIME-CV
NCT07037433
P3Active, not recruitingAtherosclerotic Cardiovascular Disease; Overweight128002028-06-30
MARITIME-HF
NCT07037459
P3RecruitingHeart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction50562028-06-30
Sotorasib
NCT07172919
P2RecruitingAdvanced Solid Tumors142028-07-01 (+8 mo)
Inebilizumab
NCT06570798
P2RecruitingSystemic Lupus Erythematosus; Active Refractory Rheumatoid Arthritis2202028-08-06 (+20 mo)
MARITIME-T2D-3
NCT07866066
P3RecruitingDiabetes Mellitus, Type 213002028-09-06
CodeBreaK 301
NCT06252649
P3RecruitingMetastatic Colorectal Cancer4502028-09-25 (+17 mo)
Xaluritamig
NCT06691984
P3Active, not recruitingMetastatic Castration-resistant Prostate Cancer7072029-01-02 (+4 mo)
DeLLphi-312
NCT07005128
P3Active, not recruitingSmall-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer3502029-01-04
Etelcalcetide
NCT03633708
P3RecruitingSecondary Hyperparathyroidism; Chronic Kidney Disease562029-01-31 (+72 mo)
DeLLphi-309
NCT06745323
P2Active, not recruitingSmall Cell Lung Cancer (SCLC)2522029-08-10 (+32 mo)
Blinatumomab
NCT04994717
P3Active, not recruitingNewly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)3032029-09-07 (+50 mo)
ROMISTER
NCT07700238
P3RecruitingPrimary Immune Thrombocytopenia1262029-09-14
Dazodalibep
NCT06747949
P3RecruitingSjögren's Syndrome8442029-12-11 (+4 mo)
Xaluritamig
NCT07213674
P3RecruitingMetastatic Castration-resistant Prostate Cancer7502030-01-07 (+16 mo)
BEAN
NCT04528082
P3RecruitingBehçet Disease602030-02-07 (+61 mo)
THYME
NCT06987539
P2RecruitingGeneralized Myasthenia Gravis152030-03-13 (+2 mo)
DeLLphi-305
NCT06211036
P3Active, not recruitingExtensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer5632030-04-02 (+31 mo)
DeLLphi-306
NCT06117774
P3Active, not recruitingLimited Stage Small Cell Lung Cancer; Small Cell Lung Cancer4042030-04-20 (+42 mo)
Blinatumomab
NCT07134088
P1/2Active, not recruitingRelapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia; Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia1042031-03-06 (+27 mo)
Inebilizumab
NCT07222553
P2RecruitingImmunoglobulin G4-related Disease152031-06-10
MERCURY
NCT07598825
P3RecruitingAutoimmune Hepatitis; AIH1802031-07-30
MOMENT
NCT07851220
P3RecruitingGlomerulonephritis, Membranous1592031-09-27
Olpasiran
NCT07136012
P3RecruitingCardiovascular Disease110002031-10-20
AUDAX
NCT07223190
P3Not yet recruitingPhiladelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia5602031-12-30 (+24 mo)
Apremilast
NCT05767047
P3RecruitingBehçet's Disease; Juvenile Psoriatic Arthritis482036-03-17 (+39 mo)